Thrombolysis for intravascular thrombosis in neonates and children

Current Opinion in Pediatrics

Volumn 21, Issue 1, 2009, Pages 9-14

  Raffini, Leslie ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Fibrinolysis; Pediatrics; Plasminogen activators; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLEEDING; BLOOD CLOT LYSIS; CHILD; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; FIBRINOLYSIS; HUMAN; INFANT; LOW DRUG DOSE; NEWBORN; PATIENT MONITORING; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS;

CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FIBRINOLYTIC AGENTS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; THROMBOSIS; TREATMENT OUTCOME;

EID: 62849097433     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32831ef537     Document Type: Review

References (38)

1. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133 (6 Suppl):454S-545S.
2. Goldenberg NA. Long-term outcomes of venous thrombosis in children. Curr Opin Hematol 2005;12:370-376.
3. Parmar N, Albisetti M, Berry LR, Chan AK. The fibrinolytic system in newborns and children. Clin Lab 2006;52:115-124.
4. Parmar N, Mitchell LG, Berry LR, et al. The influence of age on in vitro plasmin generation in the presence of fibrin monomer. Acta Haematol 2006;115:141-151.
5. Albisetti M. Thrombolytic therapy in children. Thromb Res 2006;118:95-105.
6. Important drug warning regarding the use of Abbokinase (urokinase). Rockville, Maryland: US Food and Drug Administration, Center for Drug Evaluation and Research;1999. pp. 208-1448.
7. Kohler M, Sen S, Miyashita C, et al. Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. Thromb Res 1991;62:75-81.
8. Verstraete M, Su CA, Tanswell P, et al. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemost 1986;56:1-5.
9. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-2919.
10. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133 (6 Suppl):887S-968S.
11. Saxena A, Gupta R, Kumar RK, et al. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Catheterization Cardiovasc Diagn 1997;41:400-403.
12. Rosenthal DN, Friedman AH, Kleinman CS, et al. Thromboembolic complications after Fontan operations. Circulation 1995;92 (9 Suppl):II287-II293.
13. Kahn SR. The postthrombotic syndrome: progress and pitfalls. Br J Haematol 2006;134:357-365.
14. Kahn SR. The postthrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 2006;21:41-48.
15. Kahn SR, Kearon C, Julian JA, et al. Predictors of the postthrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 2005;3:718-723.
16. Armon WL. Thrombolysis for acute deep vein thrombosis (review). The Cochrane Database of Systematic Reviews 2004:CD002783.
17. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (3 Suppl):401S-428S.
18. Kuhle S, Koloshuk B, Marzinotto V, et al. A cross-sectional study evaluating postthrombotic syndrome in children. Thromb Res 2003;111:227-233.
19. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007;110:45-53.
20. Raffini L, Raybagkar D, Cahill AM, et al. May-Thurner syndrome (iliac vein compression) and thrombosis in adolescents. Pediatr Blood Cancer 2006;47:834-838.
21. Bliss S, Weinberger S, Meier M, Saint S. Clinical problem-solving. The unusual suspect. N Engl J Med 2002;347:1876-1881.
22. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
23. Janjua N, Nasar A, Lynch JK, Qureshi AI. Thrombolysis for ischemic stroke in children: data from the nationwide inpatient sample. Stroke 2007;38:1850-1854.
24. Laiho MK, Oinonen A, Sugano N, et al. Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. Eur J Vasc Endovasc Surg 2004;28:391-396.
25. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006;107:21-29.
26. Knofler R, Dinger J, Kabus M, et al. Thrombolytic therapy in children-clinical experiences with recombinant tissue-plasminogen activator. Semin Thromb Hemost 2001;27:169-174.
27. Levy M, Benson L, Burrows P, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991;118:467-472.
28. Wang M, Hays T, Balasa V, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003;25:379-386.
29. Gupta A, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001;139:682-688.
30. Hartmann J, Hussein A, Trowitzsch E, et al. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001;85:F18-F22.
31. Farnoux C, Camard O, Pinquier D, et al. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. J Pediatr 1998;133:137-140.
32. Zenz W, Zoehrer B, Levin M, et al., International Paediatric Meningococcal Thrombolysis Study Group. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med 2004;32:1777-1780.
33. Newall F, Browne M, Savoia H, et al. Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics. J Pediatr Hematol Oncol 2007;29:269-273.
34. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77:551-556.
35. Hoffmeister HM, Szabo S, Helber U, Seipel L. The thrombolytic paradox. Thromb Res 2001;103 (Suppl 1):S51-S55.
36. Manco-Johnson MJ, Nuss R. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000;136:446-453.
37. Zenz W, Arlt F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost 1997;23:321-332.
38. Enden T, Sandvik L, Klow N, et al. Catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis-the Ca Ven T study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). Am Heart J 2007;154:808-814.